Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million.
Sanofi (SNY) Signs Deal for AI-Powered Drug Development
Sanofi (SNY) inks collaboration deal with Formation Bio and OpenAI to build AI-powered software to advance drug development and create new medicines.
Sanofi partners with OpenAI: here's how it will mitigate AI related risks
Sanofi SA (EPA: SAN) is in focus today after teaming up with OpenAI to deploy artificial intelligence for drug development.
Sanofi partners with OpenAI, Formation Bio on AI-driven drug development
French drugmaker Sanofi on Tuesday announced it is collaborating with artificial intelligence company OpenAI and Formation Bio to boost its drug development projects through the use of Artificial Intelligence.
Beacon Pointe Advisors LLC Lowers Stock Position in Sanofi (NASDAQ:SNY)
Beacon Pointe Advisors LLC cut its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 3.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 40,543 shares of the company’s stock after selling 1,306 shares during the period. Beacon Pointe Advisors LLC’s holdings in Sanofi were worth $2,016,000 as of its most recent SEC filing. Other large investors have also recently made changes to their positions in the company. Envestnet Asset Management Inc. lifted its stake in Sanofi by 29.8% during the third quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock worth $152,279,000 after purchasing an additional 651,756 shares in the last quarter. Natixis Advisors L.P. raised its stake in shares of Sanofi by 15.9% in the third quarter. Natixis Advisors L.P. now owns 2,528,289 shares of the company’s stock valued at $135,618,000 after acquiring an additional 346,563 shares in the last quarter. Morgan Stanley boosted its stake in shares of Sanofi by 4.6% in the 3rd quarter. Morgan Stanley now owns 7,322,806 shares of the company’s stock valued at $392,796,000 after buying an additional 323,968 shares during the period. Clough Capital Partners L P acquired a new position in Sanofi during the 3rd quarter worth approximately $14,719,000. Finally, Boston Partners increased its holdings in Sanofi by 1.9% in the fourth quarter. Boston Partners now owns 13,032,746 shares of the company’s stock valued at $648,617,000 after buying an additional 245,682 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds. Analyst Upgrades and Downgrades A number of equities analysts recently issued reports on SNY shares. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Morgan Stanley began coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 target price on the stock. Finally, TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $55.00. View Our Latest Research Report on SNY Sanofi Price Performance SNY stock opened at $48.67 on Monday. The company has a market cap of $123.12 billion, a price-to-earnings ratio of 24.46, a PEG ratio of 1.36 and a beta of 0.61. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The firm has a 50 day moving average of $48.20 and a 200-day moving average of $48.15. Sanofi has a 12-month low of $42.63 and a 12-month high of $55.72. Sanofi (NASDAQ:SNY – Get Free Report) last posted its earnings results on Thursday, April 25th. The company reported $0.96 EPS for the quarter, hitting analysts’ consensus estimates of $0.96. Sanofi had a return on equity of 19.69% and a net margin of 10.52%. The company had revenue of $11.36 billion for the quarter, compared to the consensus estimate of $11.75 billion. As a group, equities analysts expect that Sanofi will post 4.12 EPS for the current fiscal year. Sanofi Increases Dividend The firm also recently announced an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be issued a dividend of $1.478 per share. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a yield of 2.98%. The ex-dividend date is Thursday, May 9th. Sanofi’s dividend payout ratio (DPR) is 74.37%. Sanofi Company Profile (Free Report) Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
